Anti-tumor action and clinical application of proteasome inhibitor
- First Online:
- 30 Downloads
Ubiquitin-proteasome pathway mediates the degradation of cell protein, and cell cycle, gene translation and expression, antigen presentation and inflammatory development. Proteasome inhibitor can inhibit growth and proliferation of tumor cell, induce apoptosis and reverse multipledrug resistance of tumor cell, increase the sensitivity of other chemotherapeutic drugs and radiotherapy, and is a novel class of potent anti-tumor agents.
Key wordsProteasome inhibitor Ubiquitin-proteasome pathway Tumor
Unable to display preview. Download preview PDF.
- Alberts SR, Foster NR, Morton RF, Kugler J, Schaefer P, Wiesenfeld M, Fitch TR, Steen P, Kim GP, Gill S. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study[J]. Ann Oncol 2005; 16: 1654–1661.PubMedCrossRefGoogle Scholar
- Hollmig K, Stove J, Talamo G, et al. Addition of bortezomib(Velcade) to high dose melphalan (Vel-Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM)[J]. Blood 2004; 104: 266a.Google Scholar
- Harousseau JL, Attal M, Leleu X, et al. Bortezomib (Velcade) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Preliminary results of an IFM phase II study[J]. Blood 2004; 104: 416a.Google Scholar